



Oriamide, A New Cytotoxic Cyclic Peptide Containing a Novel Amino Acid From The Marine Sponge *Theonella* Sp.

Liat Chill and Yoel Kashman*

School of Chemistry, Tel Aviv University, Tel Aviv 69978, Israel

Michael Schleyer

Oceanographic Research Institute (ORI), Durban, Republic of South Africa

Abstract. A novel cyclic peptide, oriamide (**1**) containing the new 4-propenoyl-2-tyrosylthiazole amino acid (PTT), was isolated from the marine sponge *Theonella* sp. collected in Sodwana Bay. The structure of oriamide, including the absolute configuration of all amino acids, was elucidated by spectroscopic analysis and degradation experiments. © 1997 Elsevier Science Ltd.

In the course of our program to discover potential biomedicinals from marine invertebrates¹, we isolated a new cyclic peptide from the blue marine sponge, *Theonella* sp². Marine Sponges of the genus *Theonella* have been shown to be a rich source of unique secondary metabolites with intriguing structures including cyclic peptides. The *Theonella* peptides reported to date include orbicularamide A³, keramamides A-H,J,⁴⁻⁷ theonellamides A-F⁸⁻⁹, theonellamine B¹⁰, theonellapeptolides Ia-Ie,Iid¹¹⁻¹², cyclotheonamides A-E¹³⁻¹⁴, motuporin¹⁵, theonegramide¹⁶, perthamide B¹⁷ and konbamide¹⁸.

The freeze-dried sponge collected in Sodwana Bay, at a depth of -15m, was extracted with chloroform-methanol (1:1) and then with methanol. The extracts were concentrated in vacuo and then partitioned each according to the Kupchan procedure¹⁹. The chloroform and butanol fractions of the two partitions were combined and were subjected to RP-18 and Sephadex LH-20 columns to afford oriamide (**1**, 6.8 · 10⁻³%)²⁰.

The positive FAB mass spectrum of **1** gave an (M+H)⁺ ion at *m/z* 1036. Doping the matrix with sodium chloride shifted the FABMS peak to *m/z* 1058 (M+Na)⁺. The negative FABMS gave an (MH-Na)⁻ ion at *m/z* 1014 confirming the molecular weight of 1035. Both the ¹H and ¹³C NMR spectra (Table 1) suggested that **1** was a peptide. The individual amino acids were assigned based upon comparison to literature chemical shifts, HPLC comparisons after hydrolysis, and interpretation of the 2D HMBC, HMQC, COSY and TOCSY experiments as described below. The molecular formula of **1** was established to be C₄₄H₅₄O₁₅N₉S₂Na based upon combination of FABMS and NMR data.

The ¹H NMR spectrum included signals for a 1,2,4 trisubstituted benzene (δ 7.24, 6.82, 6.73) (Table 1) which were identified as a 2,5-dihydroxybenzoyl (DHB)²¹ group by the HMQC and HMBC spectra. Gly was proposed based on the ¹H, ¹³C and the HMBC data²². Ala was assigned based upon the COSY correlations observed between the NH and the α -H and between the α -H and the β -CH₃⁶. A diaminopropionic acid (Dpr)

Table 1: NMR Data of 1

| amino acid | position | ¹ H (#H, J [Hz]) | ¹³ C | COSY | TOCSY | HMBC | |
|------------|---------------|-----------------------------|-------------------------|-------------------|------------------------|------------------------|------|
| DHB | 1 | - | 116.8 | - | - | 6.73 | |
| | 2 | - | 151.8 | - | - | 7.24, 6.82, 6.73 | |
| | 2-OH | 11.2 (1H, s) | - | - | - | - | |
| | 3 | 6.73 (1H, d, 9.0) | 118.1 | 6.82 | 7.24 | - | |
| | 4 | 6.82 (1H, dd, 2.8, 8.8) | 121.4 | 6.73, 7.24 | - | 8.99, 7.24 | |
| | 5 | - | 149.7 | - | - | 8.99, 7.24, 6.82, 6.73 | |
| | 5-OH | 8.99 (1H, s) | - | - | - | - | |
| | 6 | 7.24 (1H, d, 2.8) | 114.4 | 6.82 | 6.73 | 8.99, 6.82 | |
| | 7 | - | 168.0 | - | - | 7.24, 6.73 | |
| | Gly | NH | 8.91 (1H, bt) | - | 3.92 | - | - |
| | | α | 3.92 (2H, dq, 3.6, 6.8) | 42.7 | 8.91 | - | - |
| Ala | CO | - | 168.4 | - | - | 8.13, 3.92 | |
| | NH | 8.13 (1H, d) | - | 4.341 | 1.17 | - | |
| | α | 4.341 (1H, m) | 48.2 | 1.17 | 1.17 | 1.17 | |
| | β | 1.17 (3H, d, 7.0) | 18.7 | 4.341 | 0.72 | 4.341 | |
| Dpr | CO | - | 171.6 | - | - | 7.93, 1.17, 4.341 | |
| | NH | 7.93 (1H, d, 7.5) | - | 4.05 | 3.75, 2.45 | - | |
| | α | 4.05 (1H, m) | 51.3 | 3.75, 2.45, 7.93 | - | - | |
| | β | 3.75 (1H, m) | 41.0 | 2.45, 4.05, 7.81 | - | - | |
| | | 2.45 (1H, m) | - | 3.75, 4.05, 7.81 | 7.93 | - | |
| β-NH | 7.81 (1H, bs) | - | 3.75 | 2.45, 4.05 | - | | |
| nor-Val | CO | - | 171.5 | - | - | 8.59 | |
| | NH | 8.59 (1H, d, 7.0) | - | 4.327 | 2.25, 1.65, 1.35, 0.92 | - | |
| | α | 4.327 (1H, m) | 54.7 | - | 8.59, 2.25, 1.55, 0.92 | - | |
| | β | 2.25 (1H, m) | 32.4 | 1.55, 1.35, 4.327 | 8.59 | 0.92 | |
| | | 1.65 (1H, m) | - | 2.25 | 0.92, 1.35 | - | |
| | γ | 1.55 (1H, m) | 20.0 | 0.92 | 1.35, 2.25 | 0.92 | |
| | | 1.35 (1H, m) | - | 0.92 | 2.25, 1.65 | - | |
| | δ | 0.92 (3H, t, 7.3) | 14.1 | 1.35, 1.55 | 1.65, 4.327, 8.54 | - | |
| CO | - | 175.1 | - | - | 8.29 | | |
| Cys acid | NH | 8.15 (1H, d) | - | 4.74 | - | - | |
| | α | 4.74 (1H, m) | 49.7 | 2.71, 3.16, 8.15 | 2.71 | 2.71 | |
| | β | 2.70 (1H, m) | 50.8 | 3.16, 4.74 | 8.15 | 4.74 | |
| | | 3.16 (1H, d) | - | 2.71, 4.74 | - | - | |
| CO | - | 170.9 | - | - | 7.81, 4.74, 2.71 | | |
| PTT | 1 | - | 165.2 | - | - | 8.15, 7.39, 6.76 | |
| | 2 | 6.76 (1H, d, 16.0) | 123.7 | 7.39 | - | - | |
| | 3 | 7.39 (1H, d, 15.1) | 132.8 | 6.76 | - | - | |
| | 4 | - | 150.0 | - | - | 7.81, 7.39, 6.76 | |
| | 5 | 7.83 (1H, s) | 123.4 | - | - | - | |
| | 7 | - | 170.7 | - | - | 5.21 | |
| | 9 | 5.21 (1H, m) | 54.7 | 3.10, 3.02, 9.37 | - | - | |
| | 10-NH | 9.37 (1H, d, 8.0) | - | 5.21 | 3.10, 3.02 | - | |
| | AKMH | 11-CO | - | 164.0 | - | - | 9.37 |
| | | 12-CO | - | 197.0 | - | - | - |
| | 13 | 5.04 (1H, dd, 3.6, 9.2) | 60.4 | 8.29 | - | 0.80 | |
| | 14-NH | 8.29 (1H, d, 9.4) | - | 5.04 | 0.80 | - | |
| | 15 | 2.39 (1H, m) | 37.2 | 0.80 | - | 0.80, 0.72, 5.04 | |
| | 16 | 0.80 (3H, d, 6.9) | 16.5 | 2.39 | 8.29 | - | |


| | | | | | | |
|-----|-------|------------------------------|-------|--------------|--------------|--------------------------|
| | 17 | 1.11 (1H, m) 0.92 (1H, m) | 23.6 | 0.72 0.80 | 2.39 | 0.80, 0.72, 5.05 |
| | 18 | 0.72 (3H, t, 7.4) | 12.1 | 1.11 | - | - |
| PTT | 19 | 3.10 (1H, m) 3.02 (1H, m) | 39.5 | 5.21 5.21 | 9.37 9.37 | 7.16, 5.21 7.16, 5.21 |
| | 20 | - | 127.7 | - | - | 6.69 |
| | 21 | 6.69 (1H, d, 8.3) | 130.7 | 7.16 | - | 7.16 |
| | 22 | 7.16 (1H, d, 8.3) | 115.5 | 6.69 | - | 6.69, 9.27 |
| | 23 | - | 156.5 | - | - | 9.27, 6.69, 7.16 |
| | 23-OH | 9.27 (1H, s) | - | - | - | - |
| | 24 | 7.16 (1H, d, 8.3) | 115.5 | 6.69 | - | 6.69, 9.27 |
| | 25 | 6.69 (1H, d, 8.3) | 130.7 | 7.16 | - | 7.16 |

* The numbering in the 'right' part (1-18) is identical to the numbering in Keramamide F⁷.

moiety was suggested based upon the COSY correlations observed between the NH and the α -H, between this α -H and both of the β -H's and between the β -NH and both of the β -protons⁷. The nor-Val unit was assigned based upon interpretation of the 2D and mainly the TOCSY data in which correlations between all α -H through δ -Me protons were observed²³. The fifth amino acid of the 'left' part of 1, i.e. a cysteic acid, was determined based upon comparison to literature chemical shifts of this acid²⁴.

The 'right' part of 1 was also deduced by NMR data (Table 1), and was found to consist of three modified amino acid residues, containing an α,β -unsaturated carbonyl group conjugated with a thiazole as well as a β -amino acid moiety constituting an isoleucine like moiety⁷ *vide infra*. The presence of the thiazole ring in this half was indicated by the ¹H and ¹³C NMR spectral data [δ_{H} 7.83 (s, 1H); δ_{C} 170.7s, 123.5d, (¹J_{C-H} = 189 Hz), and 150s]. One of the thiazole substituents at C-4 was determined, based on the HMBC correlations, to be an α,β -unsaturated carbonyl moiety, namely, a propenoyl functionality. The presence of AKMH (3-amino-2-keto-4-methyl hexanoic acid), a β -amino α -keto isoleucine like acid,⁷ was proposed based upon COSY, HMBC and TOCSY data (Table 1). Most useful in establishing the AKMH-isobutyl side chain were the HMBC correlations observed between : the γ -C and the δ -CH₃ & β -H ; the β -C and the δ -CH₃ & β -H. Two pairs of two protons each in the ¹H NMR spectrum [δ_{H} 7.16 (d, 1H, J=8.3 Hz), 6.69 (d, 1H, J=8.3 Hz)] constitute an aromatic AA'BB' system (p-substituted phenol). Further data from the HMBC and TOCSY spectra allowed the assignment of this aromatic system as part of the amino acid tyrosine. The HMBC correlation between H-9 and C-7 and a NOESY correlation between NH-10 and H-13 concluded the structure determination of the 'right' part of 1. The latter half incorporates the new 4-propenoyl-2-tyrosylthiazole (PTT) acid.

NOESY data provided further conformational information on the amino acids sequence. The major interresidue NOE correlations observed were : glycine NH to DHB H-6 ; nor-Val NH to Dpr α -H, Dpr β -H and Dpr α -NH ; AKMH NH to nor-Val α -H and nor-Val β -H ; 10-NH to H-13 ; cysteic acid NH to Dpr β -NH cysteic acid α -H to Dpr β -NH.



Further corroborative evidence for the structure of **1** was obtained from the FABMS Fragmentations: 1036 (MH^+), 1014.7 ($M-Na+H$), 908.6 ($M-Na-CH_2C_6H_4OH+H$), 837.5 ($M-Cys-acid-H_2O$), 750.5 ($M-Na-DHB-Gly-Ala$), 555.4 ($M-Na-CH_2C_6H_4OH-DHB-Gly-Ala-Dpr$), 423.4 ($M-Na-DHB-Gly-Ala-Dpr-norVal-AKMH+H$), 384.4 ($M-Na-CHO-DHB-Gly-Ala-Dpr-Cys-acid-norVal$). Noteworthy is the strong resemblance of **1** to keramamide **F**⁷, both being characterized by a cyclic segment containing amino acids Dpr, AKMH and an α,β -unsaturated carbonyl group conjugated with a thiazole ring.

Chiral TLC analysis²³ of the hydrolysate of **1** and comparison with authentic samples revealed that the Ala, Dpr, nor Val and cysteic acid residues, in **1**, were of the L-form. Ozonolysis of **1**⁷ led to degradation of the tyrosylthiazole moiety to yield Tyr, while treatment of **1** with $H_2O_2/NaOH$ ⁷ transformed the C-11+N-14 moiety (AKMH) of **1** into isoleucine. The Tyr thus obtained was determined by the chiral TLC method to be D and the isoleucine was determined to be L implying that the tyrosylthiazole in **1** is D and the AKMH is L.

Oriamide contains the unprecedented amino acid, 4-propenoyl-2-tyrosylthiazole (PTT). A related thiazole amino acid was earlier reported as a constituent of the cyclic peptide keramamide **F**⁷.

Acknowledgment: We acknowledge gratefully the identification of the sponge by Dr. R.W.M. van Soest, University of Amsterdam, Holland.

Experimental Section

General experimental procedures - The ¹H and 2D NMR spectra were recorded on a Bruker ARX-500 spectrometer. The ¹³C spectrum was recorded on a Bruker 360 Spectrometer. All chemical shifts were reported in parts per million referenced against residual undeuterated DMSO (δ_H 2.49 ppm, δ_C 39.5 ppm). ¹H,

^{13}C , DEPT, COSY, HMQC, TOCSY, and HMBC spectra were recorded using standard Bruker pulse sequences. A NOESY experiment was acquired with mixing time of 300ms. FABMS were recorded on a Fisons Autospec Q mass spectrometer. TLC was conducted on MERCK precoated Kieselgel 60 F₂₅₄ plates and the spots were detected by iodine. Chiral TLC analysis was conducted on Macherey-Nagel 811056 chiralplates eluted with MeOH-H₂O-ACN (1:1:4) and the spots were detected by spraying with ninhydrin²³.

Collection and extraction.- The marine sponge *Theonella* sp. was collected in Sodwana Bay, -15m. The Freeze-dried sponge (103g) was extracted two times with EtOAc, once with MeOH-CHCl₃ (1:1) and once with MeOH.

The MeOH-CHCl₃ and MeOH extracts (1.13g and 2.87g, respectively) were concentrated in vacuo before being each partitioned according to the Kupchan procedure¹⁹. The chloroform and butanol fractions of the two partitions were combined and were applied to a reversed phase RP-18 column, successively collecting about 11x50ml fractions of a gradient of water - MeOH. Fractions 5-11 (116mg) were combined and were subjected to a sephadex LH-20 column to afford oriamide (10mg).

Oriamide (1): amorphous powder; negative FABMS (70ev) m/z (rel int) 1014.7 (MH-Na⁺,18), 908.6 (9), 837.5 (10), 750.5 (9), 555.4 (15), 423.4 (14), 384.4 (18), 339.3 (87), 265.2 (95), 215.1 (100). For ^1H and ^{13}C NMR data see Table 1.

Determination of the Stereochemistry of the amino acids Ala, Dpr, nor Val, Cys acid.

A 0.5 mg portion of 1 was dissolved in 6N HCl (ca. 0.5 ml) and was heated at 110°C for 20h, the HCl was then removed under vacuo⁷. HPLC of the hydrolysed amino acids by Marfey's method²⁵ established 4 amino acids i.e. L-Ala, L-Cys-acid, L-nor-Val and L-Dpr. The residue and authentic samples of chiral amino acids were also subjected to chiral TLC analysis on Macherey-Nagel Chiralplates eluted with MeOH-H₂O-ACN (1:1:4) and the spots were detected by spraying with ninhydrin²³. The Ala, Dpr, nor-Val and Cys-acid residues were established to be of the L form.

Determination of the stereochemistry of the tyrosyl-thiazole.

A fine stream of O₃ was bubbled into a solution of compound 1 [0.5mg of compound 1 in MeOH (0.5 ml) - CH₂Cl₂ (5ml)] for 20 sec. Dimethyl sulfide (2 drops) was then added and the reaction mixture was left over night at rt. After removal of the CH₂Cl₂ and DMSO/DMS, the residue was dissolved in 6N HCl (0.5ml) and was subjected to acid hydrolysis as described above. Chiral TLC analysis, as described above²³, established the D form of the Tyr.

Determination of the Stereochemistry of the 3-amino-2-keto-4-methyl hexanoic acid (AKMH) moiety in

PTT: To a stirred solution of compound 1 (0.5mg) in 5% NaOH (1ml) was added, dropwise, 30% H₂O₂ (200 μ l)⁷. After stirring the solution at 65°C for 20 min the reaction mixture was subjected to hydrolysis and chiral TLC analysis as described above²⁵. The Ile thus obtained, was determined to be in the L form.

References and Notes:

1. Rudi, A.; Goldberg, I.; Stein, Z.; Kashman, Y.; Benayahu, Y.; Schleyer, M. *J. Nat. Prod.* **1995**, *58*, 1702-1712.
2. The blue sponge was identified by Dr. R. Van Soest (Amsterdam) as quite close to *Theonella swinhoeii*, which is usually purple-brown, the only difference being the size of the small acantharhabds (20 mm in *T. Swinhoeii* against 10 mm here) and the virtual absence of ectosomal phyllostriaenes. Color changes of *Theonellas* due to microsymbionts are quite common.
3. Fusetani, N.; Sugawara, T.; Matsunaga S. *J. Am. Chem. Soc.* **1991**, *113*, 7811-7812
4. Kobayashi, J.; Sato, M.; Ishibashi, M.; Shigemori, H.; Nakamura, T.; Ohizumi, Y. *J. Chem. Soc. Perkin Trans. 1*, **1991**, 2609-2611.
5. Kobayashi, J.; Itagaki, F.; Shigemori, H.; Ishibashi, M.; Takahashi, K.; Ogura, M.; Nagasawa, S.; Nakamura, T.; Hirota, H.; Ohta, T.; Nozoe, S. *J. Am. Chem. Soc.* **1991**, *113*, 7812-7813.
6. Kobayashi, J.; Itagaki, F.; Shigemori, H.; Takao, T.; Shimonishi, Y.; *Tetrahedron*, **1995**, *51*, 2525-2532.
7. Itagaki, F.; Shigemori, H.; Ishibashi, M.; Nakamura, T.; Sasaki, T.; Kobayashi, J. *J. Org. Chem.* **1992**, *57*, 5540-5542.
8. Matsunaga, S.; Fusetani, N. *J. Org. Chem.* **1995**, *60*, 1177-1181.
9. Matsunaga, S.; Fusetani, N. Hashimoto, K.; Walchli, M. *J. Am. Chem. Soc.* **1989**, *111*, 2582-2588.
10. Nakamura, H.; Kobayashi, J.; Nakamura, Y.; Ohizumi, Y.; Kondo, T.; Hirata, Y. *Tetrahedron Lett.* **1986**, *27*, 4319-4322.
11. Kobayashi, M.; Lee, N.K.; Shibuya, H.; Momose, T.; Kitagawa, I. *Chem. Pharm. Bull.* **1991**, *39*, 1177-1184.
12. Kobayashi, M.; Kanzaki, K.; Katayama, S.; Ohashi, K.; Okada, H.; Ikegami, S.; Kitagawa, I. *Chem. Pharm. Bull.* **1994**, *42*, 1410-1415.
13. Fusetani, N.; Matsunaga, S.; *J. Am. Chem. Soc.* **1990**, *112*, 7053-7054.
14. Nakao, Y.; Matsunaga, S.; Fusetani, N.; *Bioorg. & Med. Chem.* **1995**, *3*, 1115-1122.
15. Dilip de Silva, E.; Williams, D.E.; Andersen, R.J.; Klix, H.; Holmes, C.F.B.; Allen, T.M. *Tetrahedron Lett.* **1992**, *33*, 1561-1564.
16. Bewley, C.A.; Faulkner, D.J. *J. Org. Chem.* **1994**, *59*, 4849-4852.
17. Gulavita, N.K.; Pomponi, S.A.; Wright, A.E.; Yarwood, D.; Sills, M.A. *Tetrahedron Lett.* **1994**, *35*, 6815-6818.
18. Kobayashi, J.; Sato, M.; Murayama, T.; Ishibashi, M.; Walch, R.; Kanai, M.; Shoji, J.; Ohizumi, Y. *J. Chem. Soc. Chem. Commun.* **1991**, 1050-1052.
19. Kupchan, S.M. et al, *J. Org. Chem.* **1977**, *43*, 2349-2357.
20. Larger amounts of **1** will be required for further bio-evaluation.
21. Fusetani, N.; Nakao, Y. ; Matsunaga, S. *Tetrahedron Lett.* **1991**, *32*, 7073-7074.
22. Hamada, T.; Sugawara, T.; Matsunaga, S.; Fusetani, N. *Tetrahedron Lett.* **1994**, *35*, 609-612.
23. Gunasekera, S.P.; Pomponi, S.A.; McCarthy, P.J. *J. Nat. Prod.* **1994**, *57*, 79-83.
24. Li, H.; Matsunaga, S.; Fusetani, N. *J. Med. Chem.* **1995**, *38*, 338-343.
25. Marfey, P. *Carlsberg Res. Commun.* **1984**, *49a*, 591-594.

(Received in UK 1 September 1997; accepted 11 September 1997)